Literature DB >> 16764539

Antisense oligonucleotide nanocapsules efficiently inhibit EWS-Fli1 expression in a Ewing's sarcoma model.

Nedjma Toub1, Jean-Rémi Bertrand, Claude Malvy, Elias Fattal, Patrick Couvreur.   

Abstract

The cytogenetic abnormality of Ewing's sarcoma is related to the presence of a balanced t(11;22) translocation expressing the EWS-Fli1 chimeric fusion protein. Oligonucleotides (ODNs) are specific compounds that inhibit gene expression at the transcriptional level. They possess a poor bioavailability and are degraded by nucleases very rapidly. Therefore, there is a strong need for the development of ODN drug delivery systems. In the present study, polyisobutylcyanoacrylate nanocapsules entrapping ODNs in their aqueous core were prepared, with high encapsulation yield (99%). Previous studies have demonstrated that such complexes were able to inhibit tumor growth in mice. Nevertheless, no information was available about their mode of action at the cellular level. The aim of this study was to investigate the efficacy of these ODN nanocapsules on cultured tumor cells. We found that nanocapsules were capable of protecting ODN against degradation. Using confocal microscopy, we observed that cell uptake and nuclear accumulation of ODNs were importantly enhanced when ODNs were associated with these nanocapsules. Consequently, a specific cellular growth inhibition and suppression of EWSFli1 fusion gene expression was noticed. In conclusion, it was demonstrated that nanocapsules as nonviral vectors show great potential for the delivery of ODNs to cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16764539     DOI: 10.1089/oli.2006.16.158

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  9 in total

Review 1.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

2.  Alternative for anti-TNF antibodies for arthritis treatment.

Authors:  Joseph Paquet; Christel Henrionnet; Astrid Pinzano; Jean-Baptiste Vincourt; Pierre Gillet; Patrick Netter; Isabelle Chary-Valckenaere; Damien Loeuille; Jacques Pourel; Laurent Grossin
Journal:  Mol Ther       Date:  2011-08-02       Impact factor: 11.454

3.  Expression of multiple membrane-associated phospholipase A1 beta transcript variants and lysophosphatidic acid receptors in Ewing tumor cells.

Authors:  Benjamin Joachim Schmiedel; Christoph Hutter; Manuela Hesse; Martin Sebastian Staege
Journal:  Mol Biol Rep       Date:  2010-12-04       Impact factor: 2.316

Review 4.  Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma.

Authors:  Balaji Ramachandran; Thangarajan Rajkumar; Gopal Gopisetty
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

Review 5.  Caveolin-1 in sarcomas: friend or foe?

Authors:  Miguel Sáinz-Jaspeado; Juan Martin-Liberal; Laura Lagares-Tena; Silvia Mateo-Lozano; Xavier Garcia del Muro; Oscar M Tirado
Journal:  Oncotarget       Date:  2011-04

6.  Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma.

Authors:  David Herrero-Martin; Argyro Fourtouna; Stephan Niedan; Lucia T Riedmann; Raphaela Schwentner; Dave N T Aryee
Journal:  Sarcoma       Date:  2011-11-10

7.  One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma.

Authors:  Guillermo Flores; Patrick J Grohar
Journal:  J Bone Oncol       Date:  2021-12-01       Impact factor: 4.072

Review 8.  Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors.

Authors:  Monica Cantile; Laura Marra; Renato Franco; Paolo Ascierto; Giuseppina Liguori; Annarosaria De Chiara; Gerardo Botti
Journal:  Med Oncol       Date:  2013-01-18       Impact factor: 3.064

9.  Influence of the internalization pathway on the efficacy of siRNA delivery by cationic fluorescent nanodiamonds in the Ewing sarcoma cell model.

Authors:  Anna Alhaddad; Catherine Durieu; Géraldine Dantelle; Eric Le Cam; Claude Malvy; François Treussart; Jean-Rémi Bertrand
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.